In the search for treatments to manage COVID-19, the antiviral medication Paxlovid has proven to be effective. During initial clinical trials, patients who took Paxlovid were less likely to have
severe outcomes related to COVID-19 infection.
Over the past few years, researchers have continued to test and track the efficacy of Paxlovid for the original strain of COVID-19 and its variants. A recent report in The Lancet medical journal, published on March 15, 2023, confirms what early research found: Taking Paxlovid within 30 days of a confirmed COVID-19 infection helped prevent hospitalizations and death compared to those who did not receive the medication. In addition, researchers found that taking the drug within the first five days of infection was 80% effective in limiting the severity of the illness.
Paxlovid is
approved for use in the United States. The U.S. Department of Health and Human Services has prepared this
fact sheet to help you learn about eligibility and how to access this medication.
To learn more, the article can be found on
The Lancet.
